Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $496.83, giving the company a market capitalization of 126.2B. It carries a P/E multiple of 32.42.
On 2026-03-02, Vertex Pharmaceuticals(VRTX) shares started trading at $480.31, with intraday highs of — and lows of —.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 0, versus its average volume of 1.5M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Senior executives at Vertex Pharmaceuticals (NasdaqGS:VRTX), including the SVP & Chief Accounting Officer and the Executive Vice President & Chief Legal Officer...
Renewed takeover speculation around CRISPR Therapeutics (NasdaqGM:CRSP) has intensified, with Vertex Pharmaceuticals cited in recent M&A blog coverage as a pote...
Vertex Pharmaceuticals (NasdaqGS:VRTX) has expanded beyond cystic fibrosis with recent approvals for Casgevy, a gene-editing therapy for sickle cell disease and...
Analyst ratings
75%
of 32 ratingsMore VRTX News
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex Study Tracks New Pain Drug in Breastfeeding Women The study, ti...
Key Points Centessa Pharmaceuticals has a promising candidate, but plenty of work remains before it can launch it. Vertex Pharmaceuticals has a rich lineup of...
A clear thread runs through Reshma Kewalramani’s career, connecting her start as a kidney doctor, her years leading drug research and development at Amgen, and...
Vertex Pharmaceuticals reported past full-year 2025 results with revenue rising to US$12.00 billion from US$11.02 billion and net income improving to US$3.95 bi...
Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatil...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.